Ocular Therapeutix
OCUL
249 hedge funds and large institutions have $2.33B invested in Ocular Therapeutix in 2025 Q4 according to their latest regulatory filings, with 59 funds opening new positions, 103 increasing their positions, 61 reducing their positions, and 20 closing their positions.
195% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 20
127% more call options, than puts
Call options by funds: $47.8M | Put options by funds: $21M
69% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 61
15% more funds holding
Funds holding: 216 → 249 (+33)
6% more capital invested
Capital invested by funds: $2.2B → $2.33B (+$125M)
18.24% less ownership
Funds ownership: 108.15% → 89.91% (-18%)
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$61.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$29.3M |
| 3 |
Janus Henderson Group
London,
|
+$26.5M |
| 4 |
D.E. Shaw & Co
New York
|
+$12.6M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VA
VR Adviser
New York
|
-$71M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$46.9M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$43.5M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$39.2M |
| 5 |
Morgan Stanley
New York
|
-$19.3M |
OCUL Hedge Fund Activity: Q4 2025 in Review
249 of the 8,267 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2025, worth a combined $2.33B — up 5.7% from $2.2B a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new OCUL positions and 20 closed out — a net gain of 39 holders — while 103 added to existing stakes and 61 trimmed.
The largest buyer was BlackRock, adding an estimated $61.3M. The largest seller was VR Adviser, cutting an estimated $71M.
- 249 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2025, up from 216 in Q3 2025.
- Funds reported $2.33B of Ocular Therapeutix stock for Q4 2025, up 5.7% quarter-over-quarter.
- 59 funds opened new Ocular Therapeutix positions in Q4 2025 and 20 closed out, a net change of +39 holders.
- The largest Ocular Therapeutix buyer in Q4 2025 was BlackRock, an estimated $61.3M added.
- The largest Ocular Therapeutix seller in Q4 2025 was VR Adviser, an estimated $71M sold.
Based on aggregated 13F filings for Q4 2025.